Wellington Management Group LLP Invests $567,000 in Acelyrin, Inc. (NASDAQ:SLRN)

Wellington Management Group LLP purchased a new stake in Acelyrin, Inc. (NASDAQ:SLRN) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 180,539 shares of the company’s stock, valued at approximately $567,000. Wellington Management Group LLP owned 0.18% of Acelyrin as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in the company. XTX Topco Ltd acquired a new position in Acelyrin in the fourth quarter valued at about $33,000. 4WEALTH Advisors Inc. acquired a new position in shares of Acelyrin in the 4th quarter valued at approximately $35,000. Hsbc Holdings PLC bought a new stake in Acelyrin during the 4th quarter worth approximately $36,000. RPO LLC acquired a new stake in Acelyrin during the 4th quarter worth approximately $46,000. Finally, ProShare Advisors LLC raised its holdings in Acelyrin by 28.5% during the 4th quarter. ProShare Advisors LLC now owns 25,307 shares of the company’s stock worth $79,000 after buying an additional 5,617 shares during the period. Institutional investors own 87.31% of the company’s stock.

Acelyrin Price Performance

Acelyrin stock opened at $2.27 on Friday. The company has a 50 day moving average of $2.29 and a 200-day moving average of $2.64. Acelyrin, Inc. has a twelve month low of $1.85 and a twelve month high of $7.25. The stock has a market capitalization of $229.17 million, a PE ratio of -0.92 and a beta of 1.07.

Acelyrin (NASDAQ:SLRN) last announced its earnings results on Wednesday, May 14th. The company reported ($0.55) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.95) by $0.40. Equities analysts anticipate that Acelyrin, Inc. will post -2.53 EPS for the current fiscal year.

Insider Transactions at Acelyrin

In related news, CEO Mina Kim sold 17,986 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $2.74, for a total transaction of $49,281.64. Following the completion of the transaction, the chief executive officer now owns 671,753 shares in the company, valued at approximately $1,840,603.22. This represents a 2.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 13.60% of the stock is owned by insiders.

Acelyrin Company Profile

Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.